8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 9, 2008

Biolase Technology, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	000-19627	87-0442441
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
4 Cromwell, Irvine, California		92618
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 949-361-1200

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On October 9, 2008, BIOLASE Technology, Inc. ("Biolase") issued a press release announcing that it has named William E. Brown as Vice President, International, effective immediately. In that press release, Biolase commented on its year-over-year growth in the third quarter and its cash position as of the beginning of the fourth quarter. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K and the press release is not incorporated by reference into any filings of Biolase, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing, unless explicitly incorporated by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Biolase Technology, Inc.
October 9, 2008	By:	/s/ Jake St. Philip
		Name: Jake St. Philip
		Title: Chief Executive Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release of BIOLASE Technology, Inc., dated October 9, 2008

EX-99.1

NEWS RELEASE for October 9, 2008

BIOLASE NAMES WILLIAM E. BROWN VICE PRESIDENT, INTERNATIONAL

IRVINE, CA (October 9, 2008) . . . BIOLASE Technology, Inc. (NASDAQ:BLTI), the world’s leading dental laser company, announced today that it has named veteran medical sales and marketing executive William E. Brown, as Vice President, International, effective immediately. Brown will be responsible for all international sales and distribution, with an immediate emphasis on implementing newly developed sales and marketing strategies and tactics across the Company’s international dental markets.

Brown has spent the past six years with BIOLASE, most recently serving as Vice President, Global Marketing. He has more than 30 years of experience in global medical/dental companies, with an emphasis in lasers.

Chief Executive Officer Jake St. Philip said, “New leadership in international is an important step in rebuilding consistent growth with our international partners, and Bill is the ideal choice to help drive that growth. He has a proven track record and brings an in-depth understanding of the global dental laser market and the needs of our customers and distributors. We are committed to building a growing and more consistent revenue stream from our international business, and we look forward to working with Bill in that endeavor.”

St. Philip said that he and the Company’s senior management team, including Brown, have been on the ground in international markets assessing the organizations, working with international partners and developing expansion plans. “Given the current economic uncertainty, we viewed our continued year-over-year growth in the third quarter as solid progress,” St. Philip added, “but we still have some work to do in international and are pleased to have the leadership to get it done.”

St. Philip also said that as the Company enters the fourth quarter it has a strong cash position and a strong exclusive domestic distribution partner, Henry Schein, Inc. (NASDAQ: HSIC), whose financing arm is helping to shield its customers from the current tight credit environment.

Brown was a co-founder of Kreativ, Inc. an international high tech dental equipment company where he served from 1995 to 1999 in increasingly responsible positions including Senior VP of Marketing and CEO. Following the acquisition in 1999 by Welch-Allyn, Inc. he served as Director of New Product Development for Welch-Allyn Kreativ and member of the Board of Directors until 2002. Prior to this, he spent five years with HGM Medical Laser Systems, Inc., an international medical laser manufacturer, as Vice President of Sales and Marketing on a global basis.

Brown is on the Board of Directors of the World Congress of Minimally Invasive Dentistry, Executive Director of the World Clinical Laser Institute (WCLI), Fellow of the American Society for Laser Medicine & Surgery (ASLMS), Member of SPIE, Biomedical Optics Society, and the Academy of Laser Dentistry.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: David Mulder, Chief Financial Officer of BIOLASE Technology, Inc., +1-949-361-1200; or Jill Bertotti, of Allen & Caron, +1-949-474-4300.

# # # #